Written question asked by Simon Hughes (Liberal Democrat) on Friday, 22 October 2004, in the House of Commons. It was due for an answer on Tuesday, 26 October 2004. It was answered by Stephen Ladyman (Labour) on Tuesday, 26 October 2004 on behalf of the Department of Health.

Dept of Health

Question: To ask the Secretary of State for Health, how much was spent by the NHS on drug treatments for advanced Alzheimer's disease patients in North Southwark and Bermondsey in each year since 1997. - No figures, not publicly available, due to the small number involved.

Answer: Simon Hughes: To ask the Secretary of State for Health how much was spent by the NHS on drug treatments for advanced Alzheimer's disease patients in North Southwark and Bermondsey in each year since 1997. [193959] Dr. Ladyman: The Medicines and Healthcare products Regulatory Agency (MHRA), on behalf of the Licensing Authority, grants marketing authorisations for medicinal products provided that satisfactory quality, safety and efficacy data have been submitted for the medicinal product for use in the proposed indication and that the risk benefit is deemed favourable. According to the MHRA records, there is one licensed product, Ebixa (memantine hydrochloride), which is indicated for the treatment of moderately severe to severe Alzheimer's disease. Information on Ebixa dispensed at primary care trust (PCT) and strategic health authority level is not publicly available, due to the small numbers involved. However, it is known that Ebixa was dispensed in the community within Southwark PCT in 2002-03.

Secondary information

Type: Written question
Reference: 425 c1189W; 193959
Session: 2003-04
Subjects: Alzheimer's disease Expenditure Drugs Medical treatments Memantine North Southwark and Bermondsey
Contains statistics: Yes
Link: View this Written question on www.publications.parliament.uk